251 related articles for article (PubMed ID: 27582411)
1. The PiCT
Brisset AC; Ferrández A; Krause M; Rathbun S; Marlar R; Korte W
J Thromb Haemost; 2016 Nov; 14(11):2187-2193. PubMed ID: 27582411
[TBL] [Abstract][Full Text] [Related]
2. Accuracy, reproducibility and costs of different laboratory assays for the monitoring of unfractionated heparin in clinical practice: a prospective evaluation study and survey among Swiss institutions.
Bürki S; Brand B; Escher R; Wuillemin WA; Nagler M
BMJ Open; 2018 Jun; 8(6):e022943. PubMed ID: 29886450
[TBL] [Abstract][Full Text] [Related]
3. A comparison of red blood cell transfusion utilization between anti-activated factor X and activated partial thromboplastin monitoring in patients receiving unfractionated heparin.
Belk KW; Laposata M; Craver C
J Thromb Haemost; 2016 Nov; 14(11):2148-2157. PubMed ID: 27543785
[TBL] [Abstract][Full Text] [Related]
4. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
[TBL] [Abstract][Full Text] [Related]
5. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion.
Guervil DJ; Rosenberg AF; Winterstein AG; Harris NS; Johns TE; Zumberg MS
Ann Pharmacother; 2011 Jul; 45(7-8):861-8. PubMed ID: 21712506
[TBL] [Abstract][Full Text] [Related]
6. A comparative trial of anti-factor Xa levels versus the activated partial thromboplastin time for heparin monitoring.
Vandiver JW; Vondracek TG
Hosp Pract (1995); 2013 Apr; 41(2):16-24. PubMed ID: 23545756
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of a Calculation-Free Weight-Based Unfractionated Heparin Nomogram With Anti-Xa Level Monitoring Compared With Activated Partial Thromboplastin Time.
Kindelin NM; Anthes AM; Providence SM; Zhao X; Aspinall SL
Ann Pharmacother; 2021 May; 55(5):575-583. PubMed ID: 32964730
[TBL] [Abstract][Full Text] [Related]
8. Monitoring effects of direct FXa-inhibitors with a new one-step prothrombinase-induced clotting time (PiCT) assay: comparative in vitro investigation with heparin, enoxaparin, fondaparinux and DX 9065a.
Graff J; Picard-Willems B; Harder S
Int J Clin Pharmacol Ther; 2007 Apr; 45(4):237-43. PubMed ID: 17474542
[TBL] [Abstract][Full Text] [Related]
9. Performance Assessment of a Multifaceted Unfractionated Heparin Dosing Protocol in Adult Patients on Extracorporeal Membrane Oxygenator.
Al-Jazairi A; Raslan S; Al-Mehizia R; Dalaty HA; De Vol EB; Saad E; Alanazi M; Owaidah T
Ann Pharmacother; 2021 May; 55(5):592-604. PubMed ID: 32959678
[TBL] [Abstract][Full Text] [Related]
10. Monitoring of unfractionated heparin with rotational thrombelastometry using the prothrombinase-induced clotting time reagent (PiCT®).
Schaden E; Jilch S; Hacker S; Schober A; Kozek-Langenecker S
Clin Chim Acta; 2012 Dec; 414():202-5. PubMed ID: 23041210
[TBL] [Abstract][Full Text] [Related]
11. Establishing a new target range for unfractionated heparin for acute coronary syndromes.
Lee MS; Menon V; Schappert J; Wilentz JR; Singh V; Hochman JS
J Thromb Thrombolysis; 2004 Apr; 17(2):121-6. PubMed ID: 15306747
[TBL] [Abstract][Full Text] [Related]
12. Heparin dosage, level, and resistance in SARS-CoV2 infected patients in intensive care unit.
Novelli C; Borotto E; Beverina I; Punzi V; Radrizzani D; Brando B
Int J Lab Hematol; 2021 Dec; 43(6):1284-1290. PubMed ID: 33855802
[TBL] [Abstract][Full Text] [Related]
13. Antifactor Xa levels vs. activated partial thromboplastin time for monitoring unfractionated heparin. A pilot study.
Samuel S; Allison TA; Sharaf S; Yau G; Ranjbar G; Mckaig N; Nguyen A; Escobar M; Choi HA
J Clin Pharm Ther; 2016 Oct; 41(5):499-502. PubMed ID: 27381025
[TBL] [Abstract][Full Text] [Related]
14. Comparison between activated clotting time and anti-activated factor X activity for the monitoring of unfractionated heparin therapy in patients with aortic aneurysm undergoing an endovascular procedure.
Dieplinger B; Egger M; Luft C; Hinterreiter F; Pernerstorfer T; Haltmayer M; Mueller T
J Vasc Surg; 2018 Aug; 68(2):400-407. PubMed ID: 29571622
[TBL] [Abstract][Full Text] [Related]
15. Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin.
Vandiver JW; Vondracek TG
Pharmacotherapy; 2012 Jun; 32(6):546-58. PubMed ID: 22531940
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Managing Factor Xa Inhibitor to Unfractionated Heparin Transitions by aPTT Versus a Treatment Guideline Utilizing Heparin Anti-Xa Levels.
Dingus SJ; Smith AR; Dager WE; Zochert S; Nothdurft SA; Gulseth MP
Ann Pharmacother; 2022 Dec; 56(12):1289-1298. PubMed ID: 35499336
[TBL] [Abstract][Full Text] [Related]
17. Agreement between activated partial thromboplastin time and anti-Xa activity in critically ill patients receiving therapeutic unfractionated heparin.
Ratano D; Alberio L; Delodder F; Faouzi M; Berger MM
Thromb Res; 2019 Mar; 175():53-58. PubMed ID: 30708169
[TBL] [Abstract][Full Text] [Related]
18. The uncalibrated prothrombinase-induced clotting time test. Equally convenient but more precise than the aPTT for monitoring of unfractionated heparin.
Korte W; Jovic R; Hollenstein M; Degiacomi P; Gautschi M; Ferrández A
Hamostaseologie; 2010 Nov; 30(4):212-6. PubMed ID: 21057708
[TBL] [Abstract][Full Text] [Related]
19. [Theophylline adenosine dipyridamole (CTAD) and citrate evaluation to survey unfractionated heparin treatment: a delayed centrifugation validation for anti-Xa measurement?].
Billoir P; Clavier T; Guilbert A; Barbay V; Chrétien MH; Fresel M; Abriou C; Girault C; Le Cam Duchez V
Ann Biol Clin (Paris); 2020 Feb; 78(1):27-34. PubMed ID: 32108577
[TBL] [Abstract][Full Text] [Related]
20. Anticoagulation Monitoring with Activated Partial ThromboPlastin Time and Anti-Xa Activity in Intensive Care Unit Patients: Interest of Thrombin Generation Assay.
Billoir P; Elie T; Levy JH; Besnier E; Dureuil B; Veber B; Le Cam-Duchez V; Clavier T
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
